FDA inspection
Boehringer Ingelheim Pharma GmbH & Co. KG: FDA inspection ending May 15, 2025
FDA inspection 1315938 · Voluntary Action Indicated (VAI) · Ingelheim am Rhein
Key facts
| Inspection ID | 1315938 |
|---|---|
| Firm | Boehringer Ingelheim Pharma GmbH & Co. KG |
| FEI number | 3002806556 |
| Address | Boehringer Ingelheim KG., Binger Str. 173 |
| City | Ingelheim am Rhein |
| Country | Germany |
| Fiscal year | 2025 |
| Inspection end date | May 15, 2025 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data